Table 1.

Clinical features of PDAC patients analyzed by ELISA

Characteristics			N	%a
Gender
	Male		39	57
	Female		30	43
Age (y)
	Mean	63	-	-
	Range	42-84	-	-
Stageb
	IB		1	2
	IIA		7	10
	IIB		29	42
	III		10	14
	IV		22	32
Grading
	Not reported		32	46
	1		4	6
	2		16	23
	3		17	25
Primary site
	Head		49	71
	Body		6	9
	Tail		5	7
	Body-Tail		9	13
ECOG PS
	Not reported		10	14
	0		32	47
	1		25	36
	≥2		2	3
Surgery with radical intent
	Yes		39	57
	No		30	43
Baseline CA19.9 (IU/ml)
	Evaluable		63	91
	Mean	3052	-	-
	Median	500	-	-
	Range	2- > 12000	-	-
First-line chemotherapyc
	Evaluable		59	86
	Gem		43	73
	Gem/Oxal		10	17
	Gem/5-FU		3	5
	Non-Gem		1	2
	No CT		2	3
ENOA1,2 Reactivity
	Evaluable		50	73
	Positive		34	68
	Negative		16	32

ECOG PS eastern cooperative oncology group performance status, 5-FU 5-fluorouracil, Gem gemcitabine, Oxal oxaliplatin, CT chemotherapy.

^aRounded percentages.

^bClassified according to the TMN classification of malignant tumor of the pancreas (UICC).

^cFirst-line chemotherapy refers to palliative chemotherapy administered for relapsed, locally advanced inoperable, or metastatic disease.